Abbott’s Xience V Drives Fourth-Quarter Vascular Sales Up 60%
This article was originally published in The Gray Sheet
Executive Summary
Abbott's vascular device revenue soared almost 60% in the fourth quarter to $663 million on the strength of the Xience V everolimus-eluting stent, the firm reported Jan. 21
You may also be interested in...
Abbott’s Eye On Diversity Leads To $2.8 Bil. Advanced Medical Optics Buy
Abbott is betting that its $2.8 billion purchase of struggling laser vision correction, cataract surgery and contact lens care product maker Advanced Medical Optics will pay off once the economy recovers
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Abbott remains confident that it will gain 25% to 30% share of the U.S. drug-eluting stent market over the next year now that it has launched its Xience V everolimus-eluting stent
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.